Neutralizing and binding antibody dynamics following primary and booster COVID-19 vaccination among healthcare workers.

Publication date: Feb 14, 2025

Vaccine-induced neutralizing antibodies (NAbs) are key for COVID-19 protective-immunity. As the efficacy of SARS-CoV-2 vaccines declines over time and variants of the virus continue to emerge, the need for booster doses of vaccine remains on the agenda. The aim of this study was to assess NAbs dynamics and its correlation with anti-RBD IgG levels during the nine-month follow-up period after primary-CoronaVac vaccination and booster vaccinations to evaluate vaccination strategies. This prospective longitudinal observational study followed 226 healthcare workers who received primary (two doses CoronaVac) and booster (CoronaVac or BNT162b2) immunization. Serum samples were collected at four different time points, two after primary vaccination and two after booster. Anti-RBD IgG antibody levels were assessed with the SARS CoV-2 IgG-II-QUANT kit (Abbott, USA) and neutralizing antibody levels were determined with the ACE2-RBD-Neutralization-Assay (Dia-Pro, Italy) using a surrogate virus neutralization method. Factors affecting antibody response were analyzed. Statistical analysis was performed with IBM-SPSS-22. 0. One month after the second dose of CoronaVac, 79. 2% of participants had NAb, but this had decreased to 49. 7% by the fourth month and was influenced by smoking, BMI and chronic diseases. Boosters, regardless of type, significantly raised NAb levels. Heterologous vaccination yielded higher NAb and anti-RBD IgG responses. Both single or double-BNT162b2 boosters resulted in similar NAb responses. There was a strong correlation between anti-RBD IgG and NAb levels following CoronaVac vaccination, leading to the identification of predictive IgG threshold for the presence of NAb. The type of booster influenced the correlation strength and threshold-value. NAbs levels decreased rapidly after primary CoronaVac vaccination. Boosters significantly increased levels while the heterologous vaccine combination induced a greater response. Anti-RBD IgG levels were able to predict the NAb response, however the correlation varied by the vaccine type, NAb response strength and the time since vaccination.

Open Access PDF

Concepts Keywords
Bnt162b2 Adult
Boosters Antibodies
Ibm Antibodies, Neutralizing
Month Antibodies, Neutralizing
Vaccinations Antibodies, Viral
Antibodies, Viral
BNT162 Vaccine
BNT162 Vaccine
BNT162b2
CoronaVac
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Health Personnel
Healthcare workers
Humans
Immunization, Secondary
Immunoglobulin G
Immunoglobulin G
Longitudinal Studies
Male
Middle Aged
Neutralizing
Prospective Studies
SARS-CoV-2
SARS-CoV-2
sVNT
Vaccination

Semantics

Type Source Name
disease MESH COVID-19
disease IDO assay
disease MESH chronic diseases
disease MESH Infectious Diseases
pathway REACTOME Reproduction
disease IDO protein
disease MESH infection
disease IDO host
drug DRUGBANK Angiotensin II
drug DRUGBANK Gold
disease IDO process
disease IDO blood
disease MESH overweight
drug DRUGBANK L-Valine
drug DRUGBANK Saquinavir
disease MESH Hypertension
disease MESH asthma
pathway KEGG Asthma
disease MESH allergy
disease MESH diabetes mellitus
drug DRUGBANK Coenzyme M
drug DRUGBANK Trestolone
disease MESH obesity
disease IDO history
drug DRUGBANK Esomeprazole
disease MESH common cold
disease MESH influenza
drug DRUGBANK Piroxicam
drug DRUGBANK Methylergometrine
drug DRUGBANK Indoleacetic acid
disease IDO acute infection
disease MESH convalescence
drug DRUGBANK Troleandomycin
disease IDO cell
disease MESH breakthrough infection

Original Article

(Visited 1 times, 1 visits today)